PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19800793-4	2009	Moreover, the effect of these derivatives was assessed by measuring their effect on IL-1beta release induced by BzATP-induced activation of differentiated THP-1 cells.	BzATP	112-117	interleukin 1 beta	Homo sapiens	84-92
18804898-5	2008	The results show that the synthetic P2X7 receptor agonist 2",3"-O-(4-benzoyl)benzoyl-ATP (BzATP), induced a concentration-dependent phosphorylation of MAPK ERK1/2, JNK and p38.	BzATP	90-95	mitogen-activated protein kinase 3	Homo sapiens	151-155
18804898-10	2008	AA and BzATP synergism in ERK1/2 activation was abolished by cyclo-oxygenase and lipoxygenase pathway inhibitors.	BzATP	7-12	mitogen activated protein kinase 3	Rattus norvegicus	26-32
18615736-7	2008	A marker of mitosis, phosphohistone-3, was reduced by BzATP and increased by UTP, suggesting that the enhancing effect of ATP on FGF2-induced proliferation was mediated by P2 purine/pyrimidine receptors.	BzATP	54-59	fibroblast growth factor 2	Rattus norvegicus	129-133
18615736-8	2008	Phosphorylation of the growth arrest-related protein kinases p38/MAPK and SAPK/JNK was strongly increased by BzATP but only weakly affected by UTP.	BzATP	109-114	mitogen activated protein kinase 14	Rattus norvegicus	61-64
18804898-5	2008	The results show that the synthetic P2X7 receptor agonist 2",3"-O-(4-benzoyl)benzoyl-ATP (BzATP), induced a concentration-dependent phosphorylation of MAPK ERK1/2, JNK and p38.	BzATP	90-95	mitogen activated protein kinase 3	Rattus norvegicus	156-162
18804898-5	2008	The results show that the synthetic P2X7 receptor agonist 2",3"-O-(4-benzoyl)benzoyl-ATP (BzATP), induced a concentration-dependent phosphorylation of MAPK ERK1/2, JNK and p38.	BzATP	90-95	mitogen-activated protein kinase 8	Rattus norvegicus	164-167
18804898-5	2008	The results show that the synthetic P2X7 receptor agonist 2",3"-O-(4-benzoyl)benzoyl-ATP (BzATP), induced a concentration-dependent phosphorylation of MAPK ERK1/2, JNK and p38.	BzATP	90-95	mitogen activated protein kinase 14	Rattus norvegicus	172-175
18804898-7	2008	Interestingly, a robust potentiation of ERK1/2 phosphorylation was elicited by co-application of BzATP and AA, whereas no differences were observed in JNK or p38 phosphosignals.	BzATP	97-102	mitogen activated protein kinase 3	Rattus norvegicus	40-46
18804898-9	2008	The potentiation of BzATP-mediated ERK1/2 phosphorylation was also observed in human embryonic kidney cells (HEK293) stably transfected with rat P2X7, but not in HEK cells expressing truncated P2X7 receptor lacking the full cytoplasmic carboxy-terminal or in those carrying the structurally related rat P2X2.	BzATP	20-25	mitogen-activated protein kinase 3	Homo sapiens	35-41
18804898-9	2008	The potentiation of BzATP-mediated ERK1/2 phosphorylation was also observed in human embryonic kidney cells (HEK293) stably transfected with rat P2X7, but not in HEK cells expressing truncated P2X7 receptor lacking the full cytoplasmic carboxy-terminal or in those carrying the structurally related rat P2X2.	BzATP	20-25	purinergic receptor P2X 2	Rattus norvegicus	303-307
18596211-5	2008	Incubation of cells with KN-62, a P2X(7)R antagonist, prevented current activation by 2"(3")-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP).	BzATP	140-145	purinergic receptor P2X 7	Homo sapiens	34-41
18596211-6	2008	Membrane permeabilization to dye induced by BzATP was also prevented by Panx1 siRNA and by carbenoxolone and mefloquine.	BzATP	44-49	pannexin 1	Homo sapiens	72-77
18596211-9	2008	Src tyrosine phosphorylation following BzATP stimulation was reduced by KN-62, TAT-P2X(7) peptide, and by the Src tyrosine inhibitor PP2 and these compounds prevented both large-conductance Panx1 currents and membrane permeabilization.	BzATP	39-44	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
18596211-9	2008	Src tyrosine phosphorylation following BzATP stimulation was reduced by KN-62, TAT-P2X(7) peptide, and by the Src tyrosine inhibitor PP2 and these compounds prevented both large-conductance Panx1 currents and membrane permeabilization.	BzATP	39-44	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	110-113
18596211-9	2008	Src tyrosine phosphorylation following BzATP stimulation was reduced by KN-62, TAT-P2X(7) peptide, and by the Src tyrosine inhibitor PP2 and these compounds prevented both large-conductance Panx1 currents and membrane permeabilization.	BzATP	39-44	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
18596211-9	2008	Src tyrosine phosphorylation following BzATP stimulation was reduced by KN-62, TAT-P2X(7) peptide, and by the Src tyrosine inhibitor PP2 and these compounds prevented both large-conductance Panx1 currents and membrane permeabilization.	BzATP	39-44	pannexin 1	Homo sapiens	190-195
18545980-6	2008	Adenosine triphosphate (ATP) and the P2X7 receptor agonist 2"-3"-O-(4-benzoylbenzoyl)ATP (BzATP) triggered an increase in intracellular calcium, thereby suggesting the expression of functional P2 receptors, including the P2X7 receptor.	BzATP	90-95	purinergic receptor P2X 7	Homo sapiens	37-50
18501702-5	2008	The P2X7R agonist 2",3"-O-(4-benzoylbenzoyl)-ATP (BzATP) significantly increased ERK activation and this activation could be completely inhibited by oxidized ATP and Brilliant blue G.	BzATP	50-55	purinergic receptor P2X 7	Homo sapiens	4-9
18501702-5	2008	The P2X7R agonist 2",3"-O-(4-benzoylbenzoyl)-ATP (BzATP) significantly increased ERK activation and this activation could be completely inhibited by oxidized ATP and Brilliant blue G.	BzATP	50-55	mitogen-activated protein kinase 1	Homo sapiens	81-84
18545980-6	2008	Adenosine triphosphate (ATP) and the P2X7 receptor agonist 2"-3"-O-(4-benzoylbenzoyl)ATP (BzATP) triggered an increase in intracellular calcium, thereby suggesting the expression of functional P2 receptors, including the P2X7 receptor.	BzATP	90-95	purinergic receptor P2X 7	Homo sapiens	221-234
18545980-7	2008	Moreover, BzATP treatment upregulated both IL-6 mRNA and protein expression.	BzATP	10-15	interleukin 6	Homo sapiens	43-47
18545980-8	2008	Synoviocytes spontaneously released low quantities of IL-6; the incubation with BzATP induced the release of larger amounts of the cytokine, and such a release was blunted by the P2X7 antagonist oxidized ATP.	BzATP	80-85	purinergic receptor P2X 7	Homo sapiens	179-183
18305394-5	2008	The rank order of agonist potency for IL-10 production was 2"-3"-O-(4-benzoyl)-benzoyl ATP (BzATP)=dATP>2-methylthio-ADP (2-meSADP).	BzATP	92-97	interleukin 10	Rattus norvegicus	38-43
18242779-6	2008	In addition, BzATP, through P2X7 receptor activation, significantly increased the phosphorylation of synapsin-I, the main presynaptic target of CaMKII.	BzATP	13-18	purinergic receptor P2X 7	Homo sapiens	28-41
18242779-6	2008	In addition, BzATP, through P2X7 receptor activation, significantly increased the phosphorylation of synapsin-I, the main presynaptic target of CaMKII.	BzATP	13-18	synapsin I	Homo sapiens	101-111
18242779-6	2008	In addition, BzATP, through P2X7 receptor activation, significantly increased the phosphorylation of synapsin-I, the main presynaptic target of CaMKII.	BzATP	13-18	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	144-150
18242779-7	2008	Both effects mediated by BzATP were inhibited by the CaMKII inhibitors KN-62 (10 microM) and KN-93 (10 microM).	BzATP	25-30	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	53-59
18039556-4	2008	Chronic exposure of C6 cells to BzATP enhanced the expression of pro-inflammatory factors including MCP-1, IL-8 and VEGF.	BzATP	32-37	mast cell protease 1-like 1	Rattus norvegicus	100-105
18039556-4	2008	Chronic exposure of C6 cells to BzATP enhanced the expression of pro-inflammatory factors including MCP-1, IL-8 and VEGF.	BzATP	32-37	vascular endothelial growth factor A	Rattus norvegicus	116-120
18027885-7	2008	P2X4 receptors are likely involved because the calcium response to BzATP was inhibited by Cu(2+), and the P2X4 modulators Zn(2+) and ivermectin (0.3-3 microM) each increased intracellular [Ca(2+)].	BzATP	67-72	purinergic receptor P2X 4	Rattus norvegicus	0-4
17474086-2	2007	Using 293 cells expressing P2X(7) receptors, we show that the P2X(7) receptor-specific ligand 2",3"-O-(4-benzoyl-benzoyl)-ATP (BzATP) induces a signaling cascade leading to the biosynthesis of biologically active Egr-1, a zinc finger transcription factor.	BzATP	127-132	purinergic receptor P2X 7	Homo sapiens	27-42
17474086-2	2007	Using 293 cells expressing P2X(7) receptors, we show that the P2X(7) receptor-specific ligand 2",3"-O-(4-benzoyl-benzoyl)-ATP (BzATP) induces a signaling cascade leading to the biosynthesis of biologically active Egr-1, a zinc finger transcription factor.	BzATP	127-132	early growth response 1	Homo sapiens	213-218
17474086-3	2007	BzATP-triggered Egr-1 biosynthesis was attenuated by the mitogen-activated protein kinase kinase inhibitor PD98059, by BAPTA-AM, the acetoxymethylester of the cytosolic Ca(2+) chelator BAPTA, and by an epidermal growth factor (EGF) receptor-specific tyrosine kinase inhibitor (AG1478).	BzATP	0-5	early growth response 1	Homo sapiens	16-21
17474086-3	2007	BzATP-triggered Egr-1 biosynthesis was attenuated by the mitogen-activated protein kinase kinase inhibitor PD98059, by BAPTA-AM, the acetoxymethylester of the cytosolic Ca(2+) chelator BAPTA, and by an epidermal growth factor (EGF) receptor-specific tyrosine kinase inhibitor (AG1478).	BzATP	0-5	epidermal growth factor receptor	Homo sapiens	202-240
17474086-4	2007	These results indicate that phosphorylation and activation of extracellular signal-regulated protein kinase ERK, elevated levels of intracellular Ca(2+) and the transactivation of the EGF receptor are essential for BzATP-induced upregulation of Egr-1.	BzATP	215-220	mitogen-activated protein kinase 1	Homo sapiens	108-111
17474086-4	2007	These results indicate that phosphorylation and activation of extracellular signal-regulated protein kinase ERK, elevated levels of intracellular Ca(2+) and the transactivation of the EGF receptor are essential for BzATP-induced upregulation of Egr-1.	BzATP	215-220	epidermal growth factor receptor	Homo sapiens	184-196
17474086-4	2007	These results indicate that phosphorylation and activation of extracellular signal-regulated protein kinase ERK, elevated levels of intracellular Ca(2+) and the transactivation of the EGF receptor are essential for BzATP-induced upregulation of Egr-1.	BzATP	215-220	early growth response 1	Homo sapiens	245-250
17474086-6	2007	Lentiviral-mediated expression of MAP kinase phosphatase-1 (MKP-1), a dual-specific phosphatase that dephosphorylates and inactivates ERK in the nucleus, inhibited Egr-1 biosynthesis following BzATP stimulation, indicating that MKP-1 functions as a nuclear shut-off device.	BzATP	193-198	dual specificity phosphatase 1	Homo sapiens	34-58
17474086-6	2007	Lentiviral-mediated expression of MAP kinase phosphatase-1 (MKP-1), a dual-specific phosphatase that dephosphorylates and inactivates ERK in the nucleus, inhibited Egr-1 biosynthesis following BzATP stimulation, indicating that MKP-1 functions as a nuclear shut-off device.	BzATP	193-198	dual specificity phosphatase 1	Homo sapiens	60-65
17474086-6	2007	Lentiviral-mediated expression of MAP kinase phosphatase-1 (MKP-1), a dual-specific phosphatase that dephosphorylates and inactivates ERK in the nucleus, inhibited Egr-1 biosynthesis following BzATP stimulation, indicating that MKP-1 functions as a nuclear shut-off device.	BzATP	193-198	early growth response 1	Homo sapiens	164-169
17474086-8	2007	Expression of a dominant-negative mutant of Elk-1 impaired BzATP-induced upregulation of Egr-1 biosynthesis.	BzATP	59-64	ETS transcription factor ELK1	Homo sapiens	44-49
17474086-8	2007	Expression of a dominant-negative mutant of Elk-1 impaired BzATP-induced upregulation of Egr-1 biosynthesis.	BzATP	59-64	early growth response 1	Homo sapiens	89-94
17032903-1	2007	Agonist properties of the P2X7 receptor (P2X7R) differ strikingly from other P2X receptors in two main ways: high concentrations of ATP (> 100 microM) are required to activate the receptor, and the ATP analog 2",3"-O-(4-benzoyl-benzoyl)ATP (BzATP) is both more potent than ATP and evokes a higher maximum current.	BzATP	244-249	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	41-46
17761513-5	2007	The P2X(7) agonist 2"(3")-O-(4-benzoylbenzoyl)adenosine 5"-trisphosphate (BzATP) was more potent than ATP, and both stimulated (86)Rb(+) efflux from erythrocytes in a dose-dependent fashion with EC(50) values of approximately 7 and approximately 309 microM, respectively.	BzATP	74-79	purinergic receptor P2X 7	Canis lupus familiaris	4-10
17618031-3	2007	Two mutants of P2X(7) receptors (P2X(7)-EGFP-I568N, -E496A) representing polymorphisms in the P2X(7) gene known to interfere with normal receptor-trafficking and with optimal assembly of its subunits, responded with much lower current amplitudes to BzATP than their wild-type counterpart.	BzATP	249-254	purinergic receptor P2X 7	Homo sapiens	15-21
17618031-4	2007	Similarly, the normal propidium ion uptake induced by BzATP at the wild-type P2X(7) receptor was abolished by the two mutants.	BzATP	54-59	purinergic receptor P2X 7	Homo sapiens	77-92
17618031-6	2007	Further, this ischemic stimulus facilitated the current response to BzATP in HEK293 cells permanently transfected with P2X(7) receptors.	BzATP	68-73	purinergic receptor P2X 7	Homo sapiens	119-125
17448897-4	2007	In this study, we report that the P2X7 agonists ATP and 3"-O-(4-benzoyl) benzoic ATP (BzATP) stimulate ROS production by RAW 264.7 murine macrophages.	BzATP	86-91	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	34-38
17448897-6	2007	In terms of nucleotide receptor specificity, RAW 264.7 macrophages that are deficient in P2X7 are greatly reduced in their capacity to generate ROS in response to BzATP treatment (both with and without LPS priming), thus supporting a role for P2X7 in this process.	BzATP	163-168	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	89-93
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 3	Mus musculus	46-50
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 1	Mus musculus	51-55
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 14	Mus musculus	57-60
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 8	Mus musculus	66-70
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 9	Mus musculus	71-75
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 8	Mus musculus	188-192
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 9	Mus musculus	193-197
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 14	Mus musculus	202-205
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 3	Mus musculus	261-265
17448897-8	2007	We observed that BzATP stimulates MAP kinase (ERK1/ERK2, p38, and JNK1/JNK2) phosphorylation and that the antioxidants N-acetylcysteine and ascorbic acid strongly attenuate BzATP-mediated JNK1/JNK2 and p38 phosphorylation but only slightly reduce BzATP-induced ERK1/ERK2 phosphorylation.	BzATP	17-22	mitogen-activated protein kinase 1	Mus musculus	266-270
17135244-7	2007	P2X7 receptors coupled to activation of phospholipase D and A2, inhibition of which suppressed BzATP-induced blebbing.	BzATP	95-100	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	0-4
17314141-5	2007	DC reactivity to anti-TF Abs disappeared almost completely on stimulation with ATP or benzoyl ATP (BzATP), as shown by immunoblot and confocal microscopy analysis.	BzATP	99-104	coagulation factor III, tissue factor	Homo sapiens	22-24
17043813-6	2007	The use of its antagonist, oxidized ATP, similarly to transfection with anti-P2X(7) siRNA caused significant reduction in the agonist-elicited ionic currents I (ATP) and I (BzATP), with a greater drop in the latter.	BzATP	173-178	purinergic receptor P2X 7	Homo sapiens	77-83
17032903-3	2007	We sought to exploit the large differences in ATP and BzATP responses between rat and mouse P2X7R to delineate regions or specific residues that may be responsible for the unique actions of these agonists at the P2X7R.	BzATP	54-59	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	92-97
17032903-5	2007	Wild-type rat P2X7R was 10 times more sensitive to ATP and 100 times more sensitive to BzATP than wild-type mouse P2X7R.	BzATP	87-92	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	14-19
16341234-4	2006	Short-term (5 min) pre-exposure to oxidized ATP (oATP), a P2X7 antagonist that does not inhibit P2X7-associated inward currents or membrane permeabilization, inhibits the activation of ERK1/2 by ATP, ADP, the P2X7 agonist 2"-3"-O-(4-benzoylbenzoyl)-ATP (BzATP), but not by UTP and UDP.	BzATP	254-259	mitogen-activated protein kinase 3	Homo sapiens	185-191
16819989-7	2006	On the other hand, cerebellar granule neuron stimulation with BzATP, in Mg(2+)-free conditions, produced extracellular calcium entrance and, as a result, a significant increase in CaMKII phosphorylation mostly in fibres, which correspond with P2X(7) subdistribution.	BzATP	62-67	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	180-186
16819989-7	2006	On the other hand, cerebellar granule neuron stimulation with BzATP, in Mg(2+)-free conditions, produced extracellular calcium entrance and, as a result, a significant increase in CaMKII phosphorylation mostly in fibres, which correspond with P2X(7) subdistribution.	BzATP	62-67	purinergic receptor P2X 7	Homo sapiens	243-249
16819989-8	2006	Immunocytochemical and microfluorimetrical experiments, using Zn(2+) and Brilliant Blue G (BBG), as a specific P2X(7) antagonist, confirmed that BzATP was acting through the P2X(7) receptor.	BzATP	145-150	purinergic receptor P2X 7	Homo sapiens	111-117
16819989-8	2006	Immunocytochemical and microfluorimetrical experiments, using Zn(2+) and Brilliant Blue G (BBG), as a specific P2X(7) antagonist, confirmed that BzATP was acting through the P2X(7) receptor.	BzATP	145-150	purinergic receptor P2X 7	Homo sapiens	174-189
16810687-4	2006	UTP and 2",3"-O-(4-benzoyl)-benzoyl ATP (BzATP) increased phosphorylation of Ser9 on GSK3beta indicating that metabotropic P2Y and ionotropic P2X receptors are coupled to GSK3beta.	BzATP	41-46	glycogen synthase kinase 3 beta	Rattus norvegicus	85-93
16810687-4	2006	UTP and 2",3"-O-(4-benzoyl)-benzoyl ATP (BzATP) increased phosphorylation of Ser9 on GSK3beta indicating that metabotropic P2Y and ionotropic P2X receptors are coupled to GSK3beta.	BzATP	41-46	glycogen synthase kinase 3 beta	Rattus norvegicus	171-179
16341234-6	2006	We also show that BzATP and ATP activate ERK1/2 by two different pathways since ERK1/2 activation by BzATP, but not by ATP, is blocked by the tryrosine kinase inhibitor, genistein, and the Src protein kinase inhibitor, tyrphostin.	BzATP	18-23	mitogen-activated protein kinase 3	Homo sapiens	41-47
16341234-6	2006	We also show that BzATP and ATP activate ERK1/2 by two different pathways since ERK1/2 activation by BzATP, but not by ATP, is blocked by the tryrosine kinase inhibitor, genistein, and the Src protein kinase inhibitor, tyrphostin.	BzATP	18-23	mitogen-activated protein kinase 3	Homo sapiens	80-86
16341234-6	2006	We also show that BzATP and ATP activate ERK1/2 by two different pathways since ERK1/2 activation by BzATP, but not by ATP, is blocked by the tryrosine kinase inhibitor, genistein, and the Src protein kinase inhibitor, tyrphostin.	BzATP	18-23	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	189-192
16341234-6	2006	We also show that BzATP and ATP activate ERK1/2 by two different pathways since ERK1/2 activation by BzATP, but not by ATP, is blocked by the tryrosine kinase inhibitor, genistein, and the Src protein kinase inhibitor, tyrphostin.	BzATP	101-106	mitogen-activated protein kinase 3	Homo sapiens	41-47
16341234-6	2006	We also show that BzATP and ATP activate ERK1/2 by two different pathways since ERK1/2 activation by BzATP, but not by ATP, is blocked by the tryrosine kinase inhibitor, genistein, and the Src protein kinase inhibitor, tyrphostin.	BzATP	101-106	mitogen-activated protein kinase 3	Homo sapiens	80-86
16341234-6	2006	We also show that BzATP and ATP activate ERK1/2 by two different pathways since ERK1/2 activation by BzATP, but not by ATP, is blocked by the tryrosine kinase inhibitor, genistein, and the Src protein kinase inhibitor, tyrphostin.	BzATP	101-106	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	189-192
15728711-2	2005	Treatments with ATP or with the P2X(7) receptor-specific ligand 2",3"-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) induced pore formation, but the effect was slower in CaSki cells expressing endogenous P2X(7) receptor than in human embryonic kidney (HEK)-293 cells expressing exogenous P2X(7) receptor (HEK-293-hP2X(7)-R).	BzATP	117-122	purinergic receptor P2X 7	Homo sapiens	32-47
16313518-8	2005	Since neither the amplitude of mIPSCs nor that of the muscimol-induced inward currents was affected by BzATP, it is assumed that BzATP acts at presynaptic P2X7 receptors.	BzATP	129-134	purinergic receptor P2X 7	Homo sapiens	155-159
16117789-7	2005	P2X7 activation on LC induced downstream signaling events, as BzATP or ATP, but neither ADP nor UTP, induced shedding of the low-affinity receptor for IgE (CD23) from Mo-LC.	BzATP	62-67	purinergic receptor P2X 7	Homo sapiens	0-4
16117789-7	2005	P2X7 activation on LC induced downstream signaling events, as BzATP or ATP, but neither ADP nor UTP, induced shedding of the low-affinity receptor for IgE (CD23) from Mo-LC.	BzATP	62-67	Fc epsilon receptor II	Homo sapiens	156-160
15728711-2	2005	Treatments with ATP or with the P2X(7) receptor-specific ligand 2",3"-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) induced pore formation, but the effect was slower in CaSki cells expressing endogenous P2X(7) receptor than in human embryonic kidney (HEK)-293 cells expressing exogenous P2X(7) receptor (HEK-293-hP2X(7)-R).	BzATP	117-122	purinergic receptor P2X 7	Homo sapiens	211-226
15728711-2	2005	Treatments with ATP or with the P2X(7) receptor-specific ligand 2",3"-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) induced pore formation, but the effect was slower in CaSki cells expressing endogenous P2X(7) receptor than in human embryonic kidney (HEK)-293 cells expressing exogenous P2X(7) receptor (HEK-293-hP2X(7)-R).	BzATP	117-122	purinergic receptor P2X 7	Homo sapiens	211-226
15456831-6	2004	Among them, only high concentrations of ATP (500 microM) and BzATP (2",3"-O-(4-benzoyl-benzoyl)-ATP triethylammonium) (100 microM) were able to induce accumulation of YO-PRO-1 in the GCL and in the nerve fiber layer, suggesting that different cell types were responding to P2X7 stimulation.	BzATP	61-66	germ cell-less 1, spermatogenesis associated	Rattus norvegicus	183-186
15269006-4	2004	Treatment with ATP and the P2X7 receptor analog 2"-3"-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) increased apoptosis significantly, in a time- and dose-related manner.	BzATP	101-106	purinergic receptor P2X 7	Homo sapiens	27-40
15269006-6	2004	The apoptotic effect of BzATP was additive in part to that of tumor necrosis factor (TNF)-alpha, and it could be attenuated by lowering extracellular calcium and by treatment with the caspase-9 inhibitor Leu-Glu-His-Asp-O-methyl-fluoromethylketone (LEHD-FMK).	BzATP	24-29	tumor necrosis factor	Homo sapiens	62-95
15269006-6	2004	The apoptotic effect of BzATP was additive in part to that of tumor necrosis factor (TNF)-alpha, and it could be attenuated by lowering extracellular calcium and by treatment with the caspase-9 inhibitor Leu-Glu-His-Asp-O-methyl-fluoromethylketone (LEHD-FMK).	BzATP	24-29	caspase 9	Homo sapiens	184-193
15269006-7	2004	Treatment with BzATP activated caspase-9, and, in contrast to TNF-alpha, it had only a mild effect on caspase-8.	BzATP	15-20	caspase 9	Homo sapiens	31-40
15269006-7	2004	Treatment with BzATP activated caspase-9, and, in contrast to TNF-alpha, it had only a mild effect on caspase-8.	BzATP	15-20	caspase 8	Homo sapiens	102-111
15269006-8	2004	Both BzATP and TNF-alpha activated caspase-3, suggesting that BzATP activates predominantly the mitochondrial apoptotic pathway.	BzATP	5-10	caspase 3	Homo sapiens	35-44
15269006-8	2004	Both BzATP and TNF-alpha activated caspase-3, suggesting that BzATP activates predominantly the mitochondrial apoptotic pathway.	BzATP	62-67	caspase 3	Homo sapiens	35-44
14741428-2	2004	Thirty minutes of exposure to the selective P2X7 agonist 2"-3"-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) resulted in the secretion of IL-1beta after either Abeta(1-42) or LPS stimulation of human macrophages that was dependent on the concentration of the stimulus used to pre-activate the cells.	BzATP	110-115	purinergic receptor P2X 7	Homo sapiens	44-48
15210579-4	2004	2 Both ATP and the nucleotide analogue 2"-3"-O-(4-benzoylbenzoyl)-ATP (BzATP) induced an 86Rb+ efflux, which was completely inhibited by the isoquinoline derivative 1-(N,O-bis[5-isoquinolinesulphonyl]-N-methyl-l-tyrosyl)-4-phenylpiperazine (KN-62), a potent P2X7 receptor antagonist.	BzATP	71-76	purinergic receptor P2X 7	Homo sapiens	258-271
14684387-4	2004	In this regard, the present studies revealed that cotreatment of macrophages with LPS and the P2X(7)-selective ligand 2"-3"-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) results in the cooperative activation of NF-kappa B DNA-binding activity and a sustained attenuation of levels of the NF-kappa B inhibitory protein I kappa B alpha.	BzATP	171-176	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	94-100
15023862-5	2004	P2Y and P2X receptor agonists ATP, uridine 5"-triphosphate (UTP) and 2",3"-O-(4-benzoyl)-benzoyl ATP (BzATP) stimulated Akt phosphorylation in primary cultures of rat cortical astrocytes.	BzATP	102-107	AKT serine/threonine kinase 1	Rattus norvegicus	120-123
15023862-6	2004	BzATP induced Akt phosphorylation in a concentration- and time-dependent manner, similar to the effect of BzATP on Akt phosphorylation in 1321N1 astrocytoma cells stably transfected with the rat P2X(7) receptor.	BzATP	0-5	AKT serine/threonine kinase 1	Homo sapiens	14-17
15023862-6	2004	BzATP induced Akt phosphorylation in a concentration- and time-dependent manner, similar to the effect of BzATP on Akt phosphorylation in 1321N1 astrocytoma cells stably transfected with the rat P2X(7) receptor.	BzATP	106-111	AKT serine/threonine kinase 1	Homo sapiens	115-118
15023862-8	2004	In rat cortical astrocytes, the positive effect of BzATP on Akt phosphorylation was independent of glutamate release.	BzATP	51-56	AKT serine/threonine kinase 1	Rattus norvegicus	60-63
15023862-10	2004	The effect of BzATP on Akt phosphorylation in rat cortical astrocytes was significantly reduced by the P2X(7) receptor antagonist Brilliant Blue G and the P2X receptor antagonist iso-pyridoxal-5"-phosphate-6-azophenyl-2",4"-disulfonic acid, but was unaffected by trinitrophenyl-ATP, oxidized ATP, suramin and reactive blue 2.	BzATP	14-19	AKT serine/threonine kinase 1	Rattus norvegicus	23-26
15023862-12	2004	Results with specific inhibitors of signal transduction pathways suggest that extracellular and intracellular calcium, PI3K and a Src family kinase are involved in the BzATP-induced Akt phosphorylation pathway.	BzATP	168-173	AKT serine/threonine kinase 1	Rattus norvegicus	182-185
15306646-4	2004	In agreement with previous findings, the widely used P2X7 agonist 2"-3"-O-(4-benzoylbenzoyl)-adenosine-5"-triphosphate (BzATP) clearly depressed field potentials (fEPSPs); however, no evidence for an involvement of P2X7 receptors could be obtained.	BzATP	120-125	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	53-57
15306646-4	2004	In agreement with previous findings, the widely used P2X7 agonist 2"-3"-O-(4-benzoylbenzoyl)-adenosine-5"-triphosphate (BzATP) clearly depressed field potentials (fEPSPs); however, no evidence for an involvement of P2X7 receptors could be obtained.	BzATP	120-125	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	215-219
15306646-11	2004	Activation of A1-coupled K+ channels by BzATP was dependent on ecto-nucleotidases, extracellular enzymes that convert ATP to adenosine.	BzATP	40-45	tripartite motif-containing 33	Mus musculus	63-67
15306646-13	2004	Taken together, our results indicate that BzATP is extracellularly catabolized to Bz-adenosine and subsequently hetero-exchanged for intracellular adenosine and then depresses mossy fiber fEPSPs through presynaptic A1 receptors rather than through P2X7 receptors.	BzATP	42-47	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	248-252
14684387-6	2004	The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone.	BzATP	31-36	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	104-119
14684387-6	2004	The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone.	BzATP	31-36	midkine	Mus musculus	197-200
14684387-6	2004	The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone.	BzATP	31-36	mitogen-activated protein kinase 1	Mus musculus	201-204
14684387-6	2004	The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone.	BzATP	261-266	midkine	Mus musculus	197-200
14684387-6	2004	The observation that U0126 and BzATP exhibit overlapping actions with respect to LPS-induced changes in I kappa B alpha levels is supported by the finding that Ras activation, which is upstream of MEK/ERK activation, is reduced upon macrophage cotreatment with BzATP and LPS compared with the effects of BzATP treatment alone.	BzATP	261-266	midkine	Mus musculus	197-200
14978243-6	2004	The mutant subunits also suppressed the P2X7-dependent pore formation as assessed by uptake of the propidium dye YO-PRO-1 (Molecular Probes, Eugene, OR) in response to 2",3"-O-(4-benzoyl)-benzoyl-ATP (BzATP) in transfected human embryonic kidney 293 cells.	BzATP	201-206	purinergic receptor P2X 7	Homo sapiens	40-44
14741428-2	2004	Thirty minutes of exposure to the selective P2X7 agonist 2"-3"-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) resulted in the secretion of IL-1beta after either Abeta(1-42) or LPS stimulation of human macrophages that was dependent on the concentration of the stimulus used to pre-activate the cells.	BzATP	110-115	interleukin 1 beta	Homo sapiens	146-154
14634045-4	2004	KN-62 and PPADS also blocked BzATP-induced IL-1beta release (EC(50) = 617 microM) with IC(50) values of 75 and 3500 nM, respectively.	BzATP	29-34	interleukin 1 beta	Homo sapiens	43-51
14741428-3	2004	Further tests on human microglia treated with BzATP (300 microM) resulted in a 1.5- and 3.5-fold enhancement of IL-1alpha and IL-1beta secretion, respectively, from cells pre-activated by 10 microM Abeta(1-42) and a 1.6- and 3.9-fold enhancement of IL-1alpha and IL-1beta secretion, respectively, from cells pre-activated by 1 microg/ml LPS.	BzATP	46-51	interleukin 1 alpha	Homo sapiens	112-121
14634045-7	2004	Two caspase inhibitors, YVAD (caspase 1) and DEVD (caspase 3), attenuated both BzATP-induced pore formation and IL-1beta release in a concentration-dependent fashion.	BzATP	79-84	caspase 1	Homo sapiens	4-11
14634045-7	2004	Two caspase inhibitors, YVAD (caspase 1) and DEVD (caspase 3), attenuated both BzATP-induced pore formation and IL-1beta release in a concentration-dependent fashion.	BzATP	79-84	caspase 1	Homo sapiens	30-39
14741428-3	2004	Further tests on human microglia treated with BzATP (300 microM) resulted in a 1.5- and 3.5-fold enhancement of IL-1alpha and IL-1beta secretion, respectively, from cells pre-activated by 10 microM Abeta(1-42) and a 1.6- and 3.9-fold enhancement of IL-1alpha and IL-1beta secretion, respectively, from cells pre-activated by 1 microg/ml LPS.	BzATP	46-51	interleukin 1 beta	Homo sapiens	126-134
14634045-7	2004	Two caspase inhibitors, YVAD (caspase 1) and DEVD (caspase 3), attenuated both BzATP-induced pore formation and IL-1beta release in a concentration-dependent fashion.	BzATP	79-84	caspase 3	Homo sapiens	51-60
14741428-3	2004	Further tests on human microglia treated with BzATP (300 microM) resulted in a 1.5- and 3.5-fold enhancement of IL-1alpha and IL-1beta secretion, respectively, from cells pre-activated by 10 microM Abeta(1-42) and a 1.6- and 3.9-fold enhancement of IL-1alpha and IL-1beta secretion, respectively, from cells pre-activated by 1 microg/ml LPS.	BzATP	46-51	interleukin 1 alpha	Homo sapiens	249-258
14741428-3	2004	Further tests on human microglia treated with BzATP (300 microM) resulted in a 1.5- and 3.5-fold enhancement of IL-1alpha and IL-1beta secretion, respectively, from cells pre-activated by 10 microM Abeta(1-42) and a 1.6- and 3.9-fold enhancement of IL-1alpha and IL-1beta secretion, respectively, from cells pre-activated by 1 microg/ml LPS.	BzATP	46-51	interleukin 1 beta	Homo sapiens	263-271
14741428-4	2004	BzATP induction of IL-1alpha and IL-1beta secretion from microglia was completely reversed by pre-incubation of the cells with the P2X7 antagonist, adenosine 5"-triphosphate 2",3"-acyclic dialcohol (oxidized ATP).	BzATP	0-5	interleukin 1 alpha	Homo sapiens	19-28
14741428-4	2004	BzATP induction of IL-1alpha and IL-1beta secretion from microglia was completely reversed by pre-incubation of the cells with the P2X7 antagonist, adenosine 5"-triphosphate 2",3"-acyclic dialcohol (oxidized ATP).	BzATP	0-5	interleukin 1 beta	Homo sapiens	33-41
14741428-4	2004	BzATP induction of IL-1alpha and IL-1beta secretion from microglia was completely reversed by pre-incubation of the cells with the P2X7 antagonist, adenosine 5"-triphosphate 2",3"-acyclic dialcohol (oxidized ATP).	BzATP	0-5	purinergic receptor P2X 7	Homo sapiens	131-135
14741428-5	2004	In contrast to its effects on IL-1alpha and IL-1beta secretion, BzATP induced TNF-alpha after LPS stimulation, but not after stimulation with Abeta(1-42), induced IL-18 secretion regardless of whether microglia were pre-activated and attenuated IL-6 secretion after either LPS or Abeta(1-42) pre-activation.	BzATP	64-69	tumor necrosis factor	Homo sapiens	78-87
14741428-5	2004	In contrast to its effects on IL-1alpha and IL-1beta secretion, BzATP induced TNF-alpha after LPS stimulation, but not after stimulation with Abeta(1-42), induced IL-18 secretion regardless of whether microglia were pre-activated and attenuated IL-6 secretion after either LPS or Abeta(1-42) pre-activation.	BzATP	64-69	interleukin 18	Homo sapiens	163-168
14741428-5	2004	In contrast to its effects on IL-1alpha and IL-1beta secretion, BzATP induced TNF-alpha after LPS stimulation, but not after stimulation with Abeta(1-42), induced IL-18 secretion regardless of whether microglia were pre-activated and attenuated IL-6 secretion after either LPS or Abeta(1-42) pre-activation.	BzATP	64-69	interleukin 6	Homo sapiens	245-249
34936028-4	2021	We previously showed that the systemic administration of the P2XR7 agonist, 2"(3")-O-(4-benzoylbenzoyl) adenosine 5-triphosphate (BzATP), enhanced the metabolism and promoted the myogenesis of new fibres in the skeletal muscles of SOD1G93A mice.	BzATP	130-135	superoxide dismutase 1, soluble	Mus musculus	231-235
14511112-6	2003	BzATP, a potent P2X7 receptor agonist, was more effective than ATP, ADP, or 2-MeSATP at enhancing IFN gamma-induced ERK1/2 phosphorylation.	BzATP	0-5	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	16-29
14511112-6	2003	BzATP, a potent P2X7 receptor agonist, was more effective than ATP, ADP, or 2-MeSATP at enhancing IFN gamma-induced ERK1/2 phosphorylation.	BzATP	0-5	interferon gamma	Mus musculus	98-107
14511112-6	2003	BzATP, a potent P2X7 receptor agonist, was more effective than ATP, ADP, or 2-MeSATP at enhancing IFN gamma-induced ERK1/2 phosphorylation.	BzATP	0-5	mitogen-activated protein kinase 3	Mus musculus	116-122
14511112-7	2003	Consistent with activation of the P2X7 receptor, periodate-oxidized ATP, a P2X7 receptor antagonist, and suramin, a non-specific P2 receptor antagonist, inhibited the effect of ATP or BzATP on IFN gamma-induced NO production, whereas pyridoxal-phosphate-6-azophenyl-2",4"-disulfonic acid (PPADS), an antagonist of several P2X receptor subtypes, was ineffective.	BzATP	184-189	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	34-47
14511112-7	2003	Consistent with activation of the P2X7 receptor, periodate-oxidized ATP, a P2X7 receptor antagonist, and suramin, a non-specific P2 receptor antagonist, inhibited the effect of ATP or BzATP on IFN gamma-induced NO production, whereas pyridoxal-phosphate-6-azophenyl-2",4"-disulfonic acid (PPADS), an antagonist of several P2X receptor subtypes, was ineffective.	BzATP	184-189	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	75-88
14511112-7	2003	Consistent with activation of the P2X7 receptor, periodate-oxidized ATP, a P2X7 receptor antagonist, and suramin, a non-specific P2 receptor antagonist, inhibited the effect of ATP or BzATP on IFN gamma-induced NO production, whereas pyridoxal-phosphate-6-azophenyl-2",4"-disulfonic acid (PPADS), an antagonist of several P2X receptor subtypes, was ineffective.	BzATP	184-189	interferon gamma	Mus musculus	193-202
11359833-7	2001	This was further confirmed by pore formation through which the uptake of Lucifer yellow and YO-PRO1 occurred on BzATP treatment.	BzATP	112-117	lamin A/C	Homo sapiens	95-99
12711624-7	2003	Release of IL-8 was triggered by UDP, ATP, alpha,beta-meATP and BzATP, but not by UTP or ADP.	BzATP	64-69	C-X-C motif chemokine ligand 8	Homo sapiens	11-15
12711624-10	2003	Release of IL-8 stimulated by BzATP was fully blocked by the P2X(7) blocker KN-62, while release triggered by ATP was only partially inhibited.	BzATP	30-35	C-X-C motif chemokine ligand 8	Homo sapiens	11-15
12711624-10	2003	Release of IL-8 stimulated by BzATP was fully blocked by the P2X(7) blocker KN-62, while release triggered by ATP was only partially inhibited.	BzATP	30-35	purinergic receptor P2X 7	Homo sapiens	61-67
11341329-10	2001	After treatment with BzATP SaOS-2 cells exhibited dramatic morphological changes consistent with those observed after P2X7-mediated apoptosis in hemopoietic cells.	BzATP	21-26	purinergic receptor P2X 7	Homo sapiens	118-122
34497300-0	2021	Monocyte-derived and M1 macrophages from ankylosing spondylitis patients released higher TNF-alpha and expressed more IL1B in response to BzATP than macrophages from healthy subjects.	BzATP	138-143	tumor necrosis factor	Homo sapiens	89-98
34497300-0	2021	Monocyte-derived and M1 macrophages from ankylosing spondylitis patients released higher TNF-alpha and expressed more IL1B in response to BzATP than macrophages from healthy subjects.	BzATP	138-143	interleukin 1 beta	Homo sapiens	118-122
34497300-5	2021	Using LPS and IFN-gamma, macrophages were skewed toward M1 type and were treated with BzATP.	BzATP	86-91	interferon gamma	Homo sapiens	14-23
34497300-7	2021	BzATP significantly increased the protein release of TNF-alpha and the expression of TNFA and IL1B in monocyte-generated macrophages.	BzATP	0-5	tumor necrosis factor	Homo sapiens	53-62
34497300-7	2021	BzATP significantly increased the protein release of TNF-alpha and the expression of TNFA and IL1B in monocyte-generated macrophages.	BzATP	0-5	tumor necrosis factor	Homo sapiens	85-89
34497300-7	2021	BzATP significantly increased the protein release of TNF-alpha and the expression of TNFA and IL1B in monocyte-generated macrophages.	BzATP	0-5	interleukin 1 beta	Homo sapiens	94-98
34497300-8	2021	Besides, BzATP treatment significantly upregulated IL1B expression, reduced TNFA and IL23A expression, and TNF-alpha release in M1 macrophages from both groups.	BzATP	9-14	interleukin 1 beta	Homo sapiens	51-55
34497300-8	2021	Besides, BzATP treatment significantly upregulated IL1B expression, reduced TNFA and IL23A expression, and TNF-alpha release in M1 macrophages from both groups.	BzATP	9-14	tumor necrosis factor	Homo sapiens	76-80
34497300-8	2021	Besides, BzATP treatment significantly upregulated IL1B expression, reduced TNFA and IL23A expression, and TNF-alpha release in M1 macrophages from both groups.	BzATP	9-14	interleukin 23 subunit alpha	Homo sapiens	85-90
34497300-8	2021	Besides, BzATP treatment significantly upregulated IL1B expression, reduced TNFA and IL23A expression, and TNF-alpha release in M1 macrophages from both groups.	BzATP	9-14	tumor necrosis factor	Homo sapiens	107-116
34497300-9	2021	Monocyte-generated and M1 macrophages from AS patients released higher TNF-alpha and expressed more IL1B in response to the same concentration of BzATP treatment respectively.	BzATP	146-151	tumor necrosis factor	Homo sapiens	71-80
34497300-9	2021	Monocyte-generated and M1 macrophages from AS patients released higher TNF-alpha and expressed more IL1B in response to the same concentration of BzATP treatment respectively.	BzATP	146-151	interleukin 1 beta	Homo sapiens	100-104
6142892-1	1984	The ATP analog, 3"-O-(4-benzoyl)benzoic adenosine triphosphate (BzATP) was an effective photoaffinity analog of ATP for labeling the sarcoplasmic reticulum Ca,Mg-ATPase.	BzATP	64-69	dynein axonemal heavy chain 8	Homo sapiens	162-168
35524380-3	2022	In the current study, we aimed to evaluate the connection between prototypic P2X7 receptor agonist, extracellular 2"(3")-O-(4-Benzoylbenzoyl)-ATP (BzATP), and the UPR pathway in macrophages.	BzATP	147-152	purinergic receptor P2X 7	Homo sapiens	77-90
35524380-8	2022	BzATP not only significantly increased the expression levels of CHOP, GADD34, ATF6, and HERP but also significantly decreases the XBP1 expression level in M1 macrophages.	BzATP	0-5	DNA damage inducible transcript 3	Homo sapiens	64-68
35524380-8	2022	BzATP not only significantly increased the expression levels of CHOP, GADD34, ATF6, and HERP but also significantly decreases the XBP1 expression level in M1 macrophages.	BzATP	0-5	protein phosphatase 1 regulatory subunit 15A	Homo sapiens	70-76
35524380-8	2022	BzATP not only significantly increased the expression levels of CHOP, GADD34, ATF6, and HERP but also significantly decreases the XBP1 expression level in M1 macrophages.	BzATP	0-5	activating transcription factor 6	Homo sapiens	78-82
35524380-8	2022	BzATP not only significantly increased the expression levels of CHOP, GADD34, ATF6, and HERP but also significantly decreases the XBP1 expression level in M1 macrophages.	BzATP	0-5	homocysteine inducible ER protein with ubiquitin like domain 1	Homo sapiens	88-92
35524380-8	2022	BzATP not only significantly increased the expression levels of CHOP, GADD34, ATF6, and HERP but also significantly decreases the XBP1 expression level in M1 macrophages.	BzATP	0-5	X-box binding protein 1	Homo sapiens	130-134
35524380-9	2022	The present study showed that BzATP induces cellular stress in M1 macrophages by elevating the expression levels of UPR genes including CHOP, GADD34, ATF6, and reducing cell viability.	BzATP	30-35	DNA damage inducible transcript 3	Homo sapiens	136-140
35524380-9	2022	The present study showed that BzATP induces cellular stress in M1 macrophages by elevating the expression levels of UPR genes including CHOP, GADD34, ATF6, and reducing cell viability.	BzATP	30-35	protein phosphatase 1 regulatory subunit 15A	Homo sapiens	142-148
35524380-9	2022	The present study showed that BzATP induces cellular stress in M1 macrophages by elevating the expression levels of UPR genes including CHOP, GADD34, ATF6, and reducing cell viability.	BzATP	30-35	activating transcription factor 6	Homo sapiens	150-154
6142892-2	1984	In contrast to 8-azido-ATP and arylazido-ATP, BzATP produced significant inhibition of ATPase activity.	BzATP	46-51	dynein axonemal heavy chain 8	Homo sapiens	87-93
6142892-4	1984	We conclude that the photodependent incorporation of BzATP is restricted to the active site because the inhibition of ATPase activity was stoichiometrically related to analog incorporation.	BzATP	53-58	dynein axonemal heavy chain 8	Homo sapiens	118-124
33563723-4	2021	In whole-cell recordings from rat spiral ganglion cultures, the purinergic agonist 2",3"-O-(4-benzoylbenzoyl)-ATP (BzATP) activated desensitizing currents in spiral ganglion neurons (SGNs), but non-desensitizing currents in glia that were blocked by P2X7R-specific antagonists.	BzATP	115-120	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	250-255
33679392-4	2020	In ST14A/Q120 rat striatal cells, we found a reduction of P2X7R expression; however, the P2X7R agonist 2"(3")-O-(4-benzoylbenzoyl)adenosine-5"-triphosphate (BzATP) induced cellular death, and this effect was fully reversed by the antagonist periodate-oxidized adenosine 5"-triphosphate (OxATP).	BzATP	157-162	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	89-94
33563723-6	2021	BzATP-gated uptake of the fluorescent dye YO-PRO-1 was reduced and slowed by P2X7R-specific antagonists.	BzATP	0-5	proline dehydrogenase	Mus musculus	45-50
33563723-6	2021	BzATP-gated uptake of the fluorescent dye YO-PRO-1 was reduced and slowed by P2X7R-specific antagonists.	BzATP	0-5	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	77-82
30793631-15	2019	Whereas activation the opening of pannexin 1 channels by BzATP reduced corneal infection with increased expression of Caspase-1 and IL-1beta.	BzATP	57-62	pannexin 1	Mus musculus	34-44
31493768-7	2020	CONCLUSION: LPS-exposure increases IL-1beta production and secretion in HUVECs, which is further intensified by P2X7R agonist, BzATP while MgSO4 inhibits IL-1beta in both presence and absence of BzATP.	BzATP	127-132	interleukin 1 alpha	Homo sapiens	35-43
31493768-7	2020	CONCLUSION: LPS-exposure increases IL-1beta production and secretion in HUVECs, which is further intensified by P2X7R agonist, BzATP while MgSO4 inhibits IL-1beta in both presence and absence of BzATP.	BzATP	127-132	purinergic receptor P2X 7	Homo sapiens	112-117
31493768-7	2020	CONCLUSION: LPS-exposure increases IL-1beta production and secretion in HUVECs, which is further intensified by P2X7R agonist, BzATP while MgSO4 inhibits IL-1beta in both presence and absence of BzATP.	BzATP	195-200	interleukin 1 alpha	Homo sapiens	35-43
31493768-7	2020	CONCLUSION: LPS-exposure increases IL-1beta production and secretion in HUVECs, which is further intensified by P2X7R agonist, BzATP while MgSO4 inhibits IL-1beta in both presence and absence of BzATP.	BzATP	195-200	purinergic receptor P2X 7	Homo sapiens	112-117
33291318-6	2020	We found that HG/BzATP exposure generated BRB breakdown by enhancing barrier permeability (trans-endothelial electrical resistance (TEER)) and reducing the levels of ZO-1 and VE-cadherin junction proteins as well as of the Cx-43 mRNA expression levels.	BzATP	17-22	tight junction protein 1	Homo sapiens	166-170
33291318-6	2020	We found that HG/BzATP exposure generated BRB breakdown by enhancing barrier permeability (trans-endothelial electrical resistance (TEER)) and reducing the levels of ZO-1 and VE-cadherin junction proteins as well as of the Cx-43 mRNA expression levels.	BzATP	17-22	cadherin 5	Homo sapiens	175-186
33291318-6	2020	We found that HG/BzATP exposure generated BRB breakdown by enhancing barrier permeability (trans-endothelial electrical resistance (TEER)) and reducing the levels of ZO-1 and VE-cadherin junction proteins as well as of the Cx-43 mRNA expression levels.	BzATP	17-22	gap junction protein alpha 1	Homo sapiens	223-228
33105696-4	2020	Pharmacology with 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (BzATP) as agonist showed dose-dependent membranal pores on RPMI-8226 (p = 0.0027) and blockade with P2X7 receptor antagonists.	BzATP	73-78	purinergic receptor P2X 7	Homo sapiens	173-186
31376190-6	2020	In particular, we evaluated whether an in vivo treatment in SOD1G93A mice with the P2X7 specific agonist 2"(3")-O-(4-Benzoylbenzoyl) adenosine5"-triphosphate (BzATP) just before the onset of a pathological neuromuscular phenotype could exert beneficial effects in the skeletal muscles.	BzATP	159-164	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	83-87
31306657-10	2019	Importantly, ghrelin dramatically inhibited NLRP3 inflammasome activation and reduced the production of mature IL-1beta both in dystrophic muscles and in lipopolysaccharide (LPS)-primed primary myoblasts induced by the NLRP3 inflammasome activator benzylated ATP (BzATP).	BzATP	264-269	ghrelin	Mus musculus	13-20
30793631-15	2019	Whereas activation the opening of pannexin 1 channels by BzATP reduced corneal infection with increased expression of Caspase-1 and IL-1beta.	BzATP	57-62	caspase 1	Mus musculus	118-127
29456508-8	2018	We find that the distal benzoyl group of BzATP lies in close proximity to Lys-127, a residue previously implicated in BzATP binding to P2X7, potentially explaining the increased potency of BzATP at rat P2X7 receptors.	BzATP	41-46	purinergic receptor P2X 7	Homo sapiens	135-139
30814932-6	2019	Consistent with this, significant YO-PRO1 uptake was promoted by the P2X7 agonist 2",3"-O-(benzoyl-4-benzoyl)-ATP (BzATP).	BzATP	115-120	proline dehydrogenase	Mus musculus	37-41
30814932-6	2019	Consistent with this, significant YO-PRO1 uptake was promoted by the P2X7 agonist 2",3"-O-(benzoyl-4-benzoyl)-ATP (BzATP).	BzATP	115-120	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	69-73
29456508-8	2018	We find that the distal benzoyl group of BzATP lies in close proximity to Lys-127, a residue previously implicated in BzATP binding to P2X7, potentially explaining the increased potency of BzATP at rat P2X7 receptors.	BzATP	41-46	purinergic receptor P2X 7	Homo sapiens	202-206
29456508-8	2018	We find that the distal benzoyl group of BzATP lies in close proximity to Lys-127, a residue previously implicated in BzATP binding to P2X7, potentially explaining the increased potency of BzATP at rat P2X7 receptors.	BzATP	118-123	purinergic receptor P2X 7	Homo sapiens	135-139
29456508-8	2018	We find that the distal benzoyl group of BzATP lies in close proximity to Lys-127, a residue previously implicated in BzATP binding to P2X7, potentially explaining the increased potency of BzATP at rat P2X7 receptors.	BzATP	118-123	purinergic receptor P2X 7	Homo sapiens	135-139
27206526-4	2016	Using MC3T3-E1 cells, we found that combined treatment with Wnt3a and the P2X7 agonist 2"(3")-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) elicited more sustained beta-catenin nuclear localization than that induced by Wnt3a alone.	BzATP	141-146	wingless-type MMTV integration site family, member 3A	Mus musculus	60-65
29061307-0	2017	PYK2 mediates BzATP-induced extracellular matrix proteins synthesis.	BzATP	14-19	protein tyrosine kinase 2 beta	Homo sapiens	0-4
29061307-6	2017	However, the effect of the interaction of 2"(3)-Omicron-(4-Benzoylbenzoyl) adenosine-5"-triphosphate (BzATP), which is the agonist of the mechanosensitive receptor P2X7, with PYK2 on ECMP production is poorly understood.	BzATP	102-107	purinergic receptor P2X 7	Homo sapiens	164-168
29061307-6	2017	However, the effect of the interaction of 2"(3)-Omicron-(4-Benzoylbenzoyl) adenosine-5"-triphosphate (BzATP), which is the agonist of the mechanosensitive receptor P2X7, with PYK2 on ECMP production is poorly understood.	BzATP	102-107	protein tyrosine kinase 2 beta	Homo sapiens	175-179
29061307-7	2017	Thus, our purpose was to investigate the effects of PYK2 on BzATP-induced ECMP production in osteoblasts.	BzATP	60-65	protein tyrosine kinase 2 beta	Homo sapiens	52-56
29061307-9	2017	Furthermore, the PYK2 inhibitor PF431394 inhibited the stimulatory effect of BzATP on the expression of type I collagen, bone sialoprotein and osteocalcin expression.	BzATP	77-82	protein tyrosine kinase 2 beta	Homo sapiens	17-21
29061307-9	2017	Furthermore, the PYK2 inhibitor PF431394 inhibited the stimulatory effect of BzATP on the expression of type I collagen, bone sialoprotein and osteocalcin expression.	BzATP	77-82	bone gamma-carboxyglutamate protein	Homo sapiens	143-154
28822016-6	2017	In contrast, KI cultures showed higher expression of P2X7 receptors, stronger responses to BzATP, an effect largely prevented by prior administration of CaV2.1 blocker omega-agatoxin IVA, small interfering RNA (siRNA)-based silencing of P2X7 receptors or the P2X7 antagonist A-804598.	BzATP	91-96	calcium channel, voltage-dependent, P/Q type, alpha 1A subunit	Mus musculus	153-159
28822016-8	2017	Calcitonin gene-related peptide (CGRP), a well-known migraine mediator, potentiated BzATP-evoked membrane permeability in WT as well as R192Q KI cultures, demonstrating its modulatory role on trigeminal sensory ganglia.	BzATP	84-89	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	0-31
28822016-8	2017	Calcitonin gene-related peptide (CGRP), a well-known migraine mediator, potentiated BzATP-evoked membrane permeability in WT as well as R192Q KI cultures, demonstrating its modulatory role on trigeminal sensory ganglia.	BzATP	84-89	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	33-37
28955239-7	2017	Results: P2X7R expression and Ca2+ permeability induced by the selective P2X7R agonist 2"-3"-O-(4-benzoylbenzoyl)ATP (BzATP) were markedly higher in SSc than control fibroblasts.	BzATP	118-123	purinergic receptor P2X 7	Homo sapiens	9-14
28955239-7	2017	Results: P2X7R expression and Ca2+ permeability induced by the selective P2X7R agonist 2"-3"-O-(4-benzoylbenzoyl)ATP (BzATP) were markedly higher in SSc than control fibroblasts.	BzATP	118-123	purinergic receptor P2X 7	Homo sapiens	73-78
28955239-8	2017	Moreover, increased alphaSMA expression, cell migration, CTGF, and collagen release were observed in lipopolysaccharides-primed SSc fibroblasts after BzATP stimulation.	BzATP	150-155	cellular communication network factor 2	Homo sapiens	57-61
28549259-10	2017	RESULTS: BzATP inhibited osteogenic medium-induced RUNX2 and OSX mRNA expression in hMOBs.	BzATP	9-14	RUNX family transcription factor 2	Homo sapiens	51-56
28549259-10	2017	RESULTS: BzATP inhibited osteogenic medium-induced RUNX2 and OSX mRNA expression in hMOBs.	BzATP	9-14	Sp7 transcription factor	Homo sapiens	61-64
28549259-15	2017	Furthermore, when recombinant human WNT3A was added to the BzATP-treated group, it rescued the reduced RUNX2 and OSX expression, and in vitro mineralization.	BzATP	59-64	Wnt family member 3A	Homo sapiens	36-41
28549259-15	2017	Furthermore, when recombinant human WNT3A was added to the BzATP-treated group, it rescued the reduced RUNX2 and OSX expression, and in vitro mineralization.	BzATP	59-64	RUNX family transcription factor 2	Homo sapiens	103-108
28549259-15	2017	Furthermore, when recombinant human WNT3A was added to the BzATP-treated group, it rescued the reduced RUNX2 and OSX expression, and in vitro mineralization.	BzATP	59-64	Sp7 transcription factor	Homo sapiens	113-116
28470940-5	2017	3"-O-(4-benzoyl) benzoyl adenosine 5"-triphosphate (BzATP), a P2X7 R agonist, induced caspase-1 activation and mature IL-1beta release, which was further neutralized by a NLRP3 inhibitor (16673-34-0).	BzATP	52-57	caspase 1	Rattus norvegicus	86-95
28470940-5	2017	3"-O-(4-benzoyl) benzoyl adenosine 5"-triphosphate (BzATP), a P2X7 R agonist, induced caspase-1 activation and mature IL-1beta release, which was further neutralized by a NLRP3 inhibitor (16673-34-0).	BzATP	52-57	interleukin 1 beta	Rattus norvegicus	118-126
28470940-5	2017	3"-O-(4-benzoyl) benzoyl adenosine 5"-triphosphate (BzATP), a P2X7 R agonist, induced caspase-1 activation and mature IL-1beta release, which was further neutralized by a NLRP3 inhibitor (16673-34-0).	BzATP	52-57	NLR family, pyrin domain containing 3	Rattus norvegicus	171-176
28470940-13	2017	In vitro studies showed that BzATP up-regulated secretion of nerve growth factor (NGF) in M1 macrophages via IL-1beta.	BzATP	29-34	interleukin 1 beta	Rattus norvegicus	109-117
27206526-4	2016	Using MC3T3-E1 cells, we found that combined treatment with Wnt3a and the P2X7 agonist 2"(3")-O-(4-benzoylbenzoyl)adenosine 5"-triphosphate (BzATP) elicited more sustained beta-catenin nuclear localization than that induced by Wnt3a alone.	BzATP	141-146	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	74-78
27206526-5	2016	Wnt3a-induced increases in beta-catenin transcriptional activity were also potentiated by treatment with BzATP.	BzATP	105-110	wingless-type MMTV integration site family, member 3A	Mus musculus	0-5
27206526-5	2016	Wnt3a-induced increases in beta-catenin transcriptional activity were also potentiated by treatment with BzATP.	BzATP	105-110	catenin (cadherin associated protein), beta 1	Mus musculus	27-39
27206526-7	2016	The potentiation of beta-catenin transcriptional activity elicited by BzATP was also inhibited by two distinct P2X7 antagonists: A 438079 and A 740003.	BzATP	70-75	catenin (cadherin associated protein), beta 1	Mus musculus	20-32
27206526-7	2016	The potentiation of beta-catenin transcriptional activity elicited by BzATP was also inhibited by two distinct P2X7 antagonists: A 438079 and A 740003.	BzATP	70-75	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	111-115
27206526-9	2016	In MC3T3-E1 cells, BzATP increased inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK3beta), a process that was blocked by A 438079 and diminished by inhibition of protein kinase C. Thus, P2X7 signaling may potentiate the canonical Wnt pathway through GSK3beta inhibition.	BzATP	19-24	glycogen synthase kinase 3 beta	Mus musculus	65-95
27206526-9	2016	In MC3T3-E1 cells, BzATP increased inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK3beta), a process that was blocked by A 438079 and diminished by inhibition of protein kinase C. Thus, P2X7 signaling may potentiate the canonical Wnt pathway through GSK3beta inhibition.	BzATP	19-24	glycogen synthase kinase 3 beta	Mus musculus	97-105
27206526-9	2016	In MC3T3-E1 cells, BzATP increased inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK3beta), a process that was blocked by A 438079 and diminished by inhibition of protein kinase C. Thus, P2X7 signaling may potentiate the canonical Wnt pathway through GSK3beta inhibition.	BzATP	19-24	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	203-207
27206526-9	2016	In MC3T3-E1 cells, BzATP increased inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK3beta), a process that was blocked by A 438079 and diminished by inhibition of protein kinase C. Thus, P2X7 signaling may potentiate the canonical Wnt pathway through GSK3beta inhibition.	BzATP	19-24	wingless-type MMTV integration site family, member 3A	Mus musculus	247-250
27206526-9	2016	In MC3T3-E1 cells, BzATP increased inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK3beta), a process that was blocked by A 438079 and diminished by inhibition of protein kinase C. Thus, P2X7 signaling may potentiate the canonical Wnt pathway through GSK3beta inhibition.	BzATP	19-24	glycogen synthase kinase 3 beta	Mus musculus	267-275
26714441-7	2016	RESULTS: The P2X7R agonist, 2"(3")-O-(4-benzoylbenzoyl)ATP (BzATP, 3-100 mum) decreased [(3) H]GABA and [(14) C]glutamate uptake by nerve terminals of the neocortex of controls and patients with epilepsy.	BzATP	60-65	purinergic receptor P2X 7	Homo sapiens	13-18
26714441-8	2016	The inhibitory effect of BzATP (100 mum) was prevented by the selective P2X7R antagonist, A-438079 (3 mum).	BzATP	25-30	purinergic receptor P2X 7	Homo sapiens	72-77
25997851-5	2015	OPC death in cultures was induced by either KA, 3"-O-(Benzoyl) benzoyl ATP (BzATP) (which stimulates the purinergic receptor P2X7), or TNFalpha, and the effects of EP3 receptor agonists and antagonists on OPC viability were examined.	BzATP	76-81	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	125-129
26099359-4	2015	The promotive effect of 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (BzATP) (a P2X7 receptor agonist) was more potent than ATP.	BzATP	79-84	purinergic receptor P2X 7	Homo sapiens	89-102
26099359-5	2015	After incubation with BzATP, the activity of Fyn, one member of the Src family of kinases, was enhanced.	BzATP	22-27	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	45-48
26099359-5	2015	After incubation with BzATP, the activity of Fyn, one member of the Src family of kinases, was enhanced.	BzATP	22-27	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	68-71
26099359-7	2015	After blocking the activity of Fyn or down-regulating the expression of Fyn, the migration of OPCs induced by BzATP was inhibited.	BzATP	110-115	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	31-34
26099359-7	2015	After blocking the activity of Fyn or down-regulating the expression of Fyn, the migration of OPCs induced by BzATP was inhibited.	BzATP	110-115	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	72-75
25318104-7	2015	Both ATP and the more specific P2X(7)R agonist 2"(3")-O-(4-benzoylbenzoyl)ATP (BzATP) induced endocytosis of CAV1, which was inhibited when MC3T3-E1 cells were pretreated with the specific P2X7R antagonist A-839977.	BzATP	79-84	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	31-38
25318104-7	2015	Both ATP and the more specific P2X(7)R agonist 2"(3")-O-(4-benzoylbenzoyl)ATP (BzATP) induced endocytosis of CAV1, which was inhibited when MC3T3-E1 cells were pretreated with the specific P2X7R antagonist A-839977.	BzATP	79-84	caveolin 1, caveolae protein	Mus musculus	109-113
25318104-7	2015	Both ATP and the more specific P2X(7)R agonist 2"(3")-O-(4-benzoylbenzoyl)ATP (BzATP) induced endocytosis of CAV1, which was inhibited when MC3T3-E1 cells were pretreated with the specific P2X7R antagonist A-839977.	BzATP	79-84	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	189-194
25318104-9	2015	Suppression of CAV1 enhanced the intracellular Ca(2+) response to BzATP, suggesting that caveolae regulate P2X(7)R signaling.	BzATP	66-71	caveolin 1, caveolae protein	Mus musculus	15-19
25318104-9	2015	Suppression of CAV1 enhanced the intracellular Ca(2+) response to BzATP, suggesting that caveolae regulate P2X(7)R signaling.	BzATP	66-71	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	107-114
25318104-10	2015	This proposed mechanism is supported by increased mineralization in CAV1 knockdown MC3T3-E1 cells treated with BzATP.	BzATP	111-116	caveolin 1, caveolae protein	Mus musculus	68-72
25059924-7	2014	In contrast, BzATP (10-100 muM) increases both ATP and ADP levels by over 100-fold at 5 min.	BzATP	13-18	latexin	Homo sapiens	27-30
24105615-4	2014	In BD monocytes, an increased P2x7r expression and Ca(2+) permeability induced by the selective P2x7r agonist 2"-3"-O-(4-benzoylbenzoyl)ATP (BzATP) was observed.	BzATP	141-146	purinergic receptor P2X 7	Homo sapiens	30-35
24913779-5	2014	In SKOV-3 cells, selective stimulation of P2X7 by 2"(3")-O-(4-benzoylbenzoyl) adenosine-5"-triphosphate (BzATP) induced a dose-dependent increase of intracellular Ca(2+) concentration ([Ca(2+)](i)) but not cell death.	BzATP	105-110	purinergic receptor P2X 7	Homo sapiens	42-46
24913779-6	2014	Instead, BzATP increased the levels of phosphorylated ERK and AKT (pERK and pAKT), with an EC(50) of 44 +- 2 and 1.27 +- 0.5 muM, respectively; 10 muM BzATP evoked a maximum effect within 15 min that lasted for 120 min.	BzATP	9-14	mitogen-activated protein kinase 1	Homo sapiens	54-57
24913779-6	2014	Instead, BzATP increased the levels of phosphorylated ERK and AKT (pERK and pAKT), with an EC(50) of 44 +- 2 and 1.27 +- 0.5 muM, respectively; 10 muM BzATP evoked a maximum effect within 15 min that lasted for 120 min.	BzATP	9-14	AKT serine/threonine kinase 1	Homo sapiens	62-65
24913779-6	2014	Instead, BzATP increased the levels of phosphorylated ERK and AKT (pERK and pAKT), with an EC(50) of 44 +- 2 and 1.27 +- 0.5 muM, respectively; 10 muM BzATP evoked a maximum effect within 15 min that lasted for 120 min.	BzATP	9-14	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	67-71
24913779-6	2014	Instead, BzATP increased the levels of phosphorylated ERK and AKT (pERK and pAKT), with an EC(50) of 44 +- 2 and 1.27 +- 0.5 muM, respectively; 10 muM BzATP evoked a maximum effect within 15 min that lasted for 120 min.	BzATP	151-156	mitogen-activated protein kinase 1	Homo sapiens	54-57
24851271-6	2014	P2X7 ligation by 2",3"-(benzoyl-4-benzoyl)-ATP (BzATP), a specific receptor agonist, was followed by an increase in intracellular Ca2+ and in the uptake of ethidium bromide.	BzATP	48-53	purinergic receptor P2X 7	Homo sapiens	0-4
24851271-8	2014	At 24 h treatment of hPDLSCs with BzATP it enhanced the release of the pro-inflammatory agents IL8 and CCL20, without influencing cell viability.	BzATP	34-39	C-X-C motif chemokine ligand 8	Homo sapiens	95-98
24851271-8	2014	At 24 h treatment of hPDLSCs with BzATP it enhanced the release of the pro-inflammatory agents IL8 and CCL20, without influencing cell viability.	BzATP	34-39	C-C motif chemokine ligand 20	Homo sapiens	103-108
24472059-4	2014	We showed that adenosine 5"-[gamma-thio]triphosphate tetralithium salt (ATPgammaS) and 2",3"-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (BzATP), two stable analogs of ATP, are able to potentiate the release of IL-1beta from human monocyte-derived macrophages induced by low concentration of lipopolysaccharide (LPS).	BzATP	141-146	interleukin 1 beta	Homo sapiens	214-222
24472059-7	2014	NLRP3 and IL-1beta mRNA expression were induced from LPS-primed macrophages, but also after 5-h treatment of BzATP as analysed by reverse transcription quantitative polymerase chain reaction.	BzATP	109-114	NLR family pyrin domain containing 3	Homo sapiens	0-5
24472059-7	2014	NLRP3 and IL-1beta mRNA expression were induced from LPS-primed macrophages, but also after 5-h treatment of BzATP as analysed by reverse transcription quantitative polymerase chain reaction.	BzATP	109-114	interleukin 1 beta	Homo sapiens	10-18
24922070-6	2014	We found that the activation of P2X7R by BzATP caused the death of AEC I by suppressing Wnt/beta-catenin signaling through stimulating glycogen synthase kinase-3beta (GSK-3beta) and proteasome.	BzATP	41-46	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	32-37
24922070-6	2014	We found that the activation of P2X7R by BzATP caused the death of AEC I by suppressing Wnt/beta-catenin signaling through stimulating glycogen synthase kinase-3beta (GSK-3beta) and proteasome.	BzATP	41-46	wingless-type MMTV integration site family, member 3A	Mus musculus	88-91
24922070-6	2014	We found that the activation of P2X7R by BzATP caused the death of AEC I by suppressing Wnt/beta-catenin signaling through stimulating glycogen synthase kinase-3beta (GSK-3beta) and proteasome.	BzATP	41-46	catenin (cadherin associated protein), beta 1	Mus musculus	92-104
24922070-6	2014	We found that the activation of P2X7R by BzATP caused the death of AEC I by suppressing Wnt/beta-catenin signaling through stimulating glycogen synthase kinase-3beta (GSK-3beta) and proteasome.	BzATP	41-46	glycogen synthase kinase 3 beta	Mus musculus	135-165
24922070-6	2014	We found that the activation of P2X7R by BzATP caused the death of AEC I by suppressing Wnt/beta-catenin signaling through stimulating glycogen synthase kinase-3beta (GSK-3beta) and proteasome.	BzATP	41-46	glycogen synthase kinase 3 beta	Mus musculus	167-176
24922070-8	2014	More importantly, Wnt3a attenuated the AEC I damage caused by intratracheal instillation of BzATP in rats or LPS in ventilated mice.	BzATP	92-97	Wnt family member 3A	Rattus norvegicus	18-23
24105615-4	2014	In BD monocytes, an increased P2x7r expression and Ca(2+) permeability induced by the selective P2x7r agonist 2"-3"-O-(4-benzoylbenzoyl)ATP (BzATP) was observed.	BzATP	141-146	purinergic receptor P2X 7	Homo sapiens	96-101
24105615-5	2014	Moreover, IL-1beta release from LPS-primed monocytes stimulated with BzATP was markedly higher in BD patients than in controls.	BzATP	69-74	interleukin 1 beta	Homo sapiens	10-18
24105615-6	2014	TNF-alpha-incubated monocytes from healthy subjects almost reproduced the findings observed in BD patients, as demonstrated by the increase in P2x7r expression and BzATP-induced Ca(2+) intake.	BzATP	164-169	tumor necrosis factor	Homo sapiens	0-9
21631954-5	2011	RESULTS: Following SE, P2X7 receptor agonist (BzATP) infusion increased TNF-alpha immunoreactivity in dentate granule cells as compared with that in saline-infused animals.	BzATP	46-51	tumor necrosis factor	Rattus norvegicus	72-81
24091672-6	2013	High concentrations of ATP and BzATP increased ethidium uptake by SCs, indicating increased membrane permeability to large molecules, a typical feature of prolonged P2X7R activation.	BzATP	31-36	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	165-170
23816751-11	2013	In LPS-primed naive rats, BzATP induced caspase-1 activation and mature IL-1beta release were neutralized by cryopyrin siRNA.	BzATP	26-31	caspase 1	Rattus norvegicus	40-49
23816751-11	2013	In LPS-primed naive rats, BzATP induced caspase-1 activation and mature IL-1beta release were neutralized by cryopyrin siRNA.	BzATP	26-31	interleukin 1 beta	Rattus norvegicus	72-80
23564500-3	2013	In non-SE animals, 2"(3")-O-(4-benzoyl)benzoyl adenosine 5"-triphosphate (BzATP, a P2X7R agonist) treatment increased only p52-Ser869 NF-kappaB phosphorylation in neuron.	BzATP	74-79	similar to Mitochondrial processing peptidase beta subunit, mitochondrial precursor (Beta-MPP; P-52)	Rattus norvegicus	123-126
23564500-5	2013	However, BzATP treatment prevented reductions in p65-Ser276, p65-Ser311, p65-Ser529, and p52-Ser869 NF-kappaB phosphorylations in CA1 and/or CA3 neurons induced by SE.	BzATP	9-14	synaptotagmin 1	Rattus norvegicus	49-52
23564500-5	2013	However, BzATP treatment prevented reductions in p65-Ser276, p65-Ser311, p65-Ser529, and p52-Ser869 NF-kappaB phosphorylations in CA1 and/or CA3 neurons induced by SE.	BzATP	9-14	synaptotagmin 1	Rattus norvegicus	61-64
23564500-5	2013	However, BzATP treatment prevented reductions in p65-Ser276, p65-Ser311, p65-Ser529, and p52-Ser869 NF-kappaB phosphorylations in CA1 and/or CA3 neurons induced by SE.	BzATP	9-14	synaptotagmin 1	Rattus norvegicus	61-64
23564500-5	2013	However, BzATP treatment prevented reductions in p65-Ser276, p65-Ser311, p65-Ser529, and p52-Ser869 NF-kappaB phosphorylations in CA1 and/or CA3 neurons induced by SE.	BzATP	9-14	similar to Mitochondrial processing peptidase beta subunit, mitochondrial precursor (Beta-MPP; P-52)	Rattus norvegicus	89-92
23564500-5	2013	However, BzATP treatment prevented reductions in p65-Ser276, p65-Ser311, p65-Ser529, and p52-Ser869 NF-kappaB phosphorylations in CA1 and/or CA3 neurons induced by SE.	BzATP	9-14	carbonic anhydrase 1	Rattus norvegicus	130-133
23564500-5	2013	However, BzATP treatment prevented reductions in p65-Ser276, p65-Ser311, p65-Ser529, and p52-Ser869 NF-kappaB phosphorylations in CA1 and/or CA3 neurons induced by SE.	BzATP	9-14	carbonic anhydrase 3	Rattus norvegicus	141-144
23564500-6	2013	Furthermore, BzATP treatment reduced SE-induced p65-Ser311, p65-Ser468, p65-Ser536, and p52-Ser869 NF-kappaB phosphorylations in astrocytes.	BzATP	13-18	synaptotagmin 1	Rattus norvegicus	48-51
23564500-6	2013	Furthermore, BzATP treatment reduced SE-induced p65-Ser311, p65-Ser468, p65-Ser536, and p52-Ser869 NF-kappaB phosphorylations in astrocytes.	BzATP	13-18	synaptotagmin 1	Rattus norvegicus	60-63
23564500-6	2013	Furthermore, BzATP treatment reduced SE-induced p65-Ser311, p65-Ser468, p65-Ser536, and p52-Ser869 NF-kappaB phosphorylations in astrocytes.	BzATP	13-18	synaptotagmin 1	Rattus norvegicus	60-63
23564500-6	2013	Furthermore, BzATP treatment reduced SE-induced p65-Ser311, p65-Ser468, p65-Ser536, and p52-Ser869 NF-kappaB phosphorylations in astrocytes.	BzATP	13-18	similar to Mitochondrial processing peptidase beta subunit, mitochondrial precursor (Beta-MPP; P-52)	Rattus norvegicus	88-91
22297175-0	2012	Mechanisms of Mg2+ inhibition of BzATP-dependent Ca2+ responses in THP-1 monocytes.	BzATP	33-38	GLI family zinc finger 2	Homo sapiens	67-72
22297175-6	2012	Treatment of THP-1 cells with 10 mMMg2+ was highly effective in reducing the time course of BzATP-induced Ca2+ decay; unlike the other modulatory protocols, Mg2+ markedly inhibited the amplitudes of slow and rapid components.	BzATP	92-97	GLI family zinc finger 2	Homo sapiens	13-18
22297175-8	2012	Priming of cells with the inflammatory stimulus LPS/IFN-gamma markedly enhanced the slower, but not rapid, phase of BzATP-induced [Ca2+]i with application of 10 mMMg2+ inhibiting both components of response.	BzATP	116-121	interferon gamma	Homo sapiens	52-61
22185840-5	2012	The P2X7 agonist 2",3"-O-(4-benzoylbenzoyl)ATP (BzATP; 300 muM) induced dynamic membrane blebbing in MC3T3-E1 osteoblast-like cells (consistent with activation of P2X7 receptors) but did not induce cell death.	BzATP	48-53	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	4-8
22185840-5	2012	The P2X7 agonist 2",3"-O-(4-benzoylbenzoyl)ATP (BzATP; 300 muM) induced dynamic membrane blebbing in MC3T3-E1 osteoblast-like cells (consistent with activation of P2X7 receptors) but did not induce cell death.	BzATP	48-53	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	163-167
22185840-6	2012	Using a Cytosensor microphysiometer, we found that 9-min exposure to BzATP (300 muM) caused a dramatic increase in proton efflux from MC3T3-E1 cells (~2-fold), which was sustained for at least 1 h. In contrast, ATP or UTP (100 muM), which activate P2 receptors other than P2X7, failed to elicit a sustained increase in proton efflux.	BzATP	69-74	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	272-276
22185840-7	2012	Specific P2X7 receptor antagonists A 438079 and A 740003 inhibited the sustained phase of the BzATP-induced response.	BzATP	94-99	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	9-22
24377098-9	2013	Whereas hypoxia did not alter their expression, BzATP upregulated P2X4 and P2X7 mRNAs; these effects were ablated in hypoxia.	BzATP	48-53	purinergic receptor P2X 4	Rattus norvegicus	66-70
23449724-4	2013	METHODS: Human organotypic retinal cultures were exposed to the P2X7R agonist 2",3"-O-(4-benzoylbenzoyl)-ATP (BzATP) and simulated ischemia (oxygen/glucose deprivation) in the presence or absence of the P2X7R antagonist, Brilliant Blue G (BBG).	BzATP	110-115	purinergic receptor P2X 7	Homo sapiens	64-69
23449724-7	2013	RESULTS: P2X7R stimulation by BzATP (100 muM) induced loss of RGC markers in human organotypic retinal cultures (HORCs), which was inhibited by BBG (1 muM).	BzATP	30-35	purinergic receptor P2X 7	Homo sapiens	9-14
23449724-7	2013	RESULTS: P2X7R stimulation by BzATP (100 muM) induced loss of RGC markers in human organotypic retinal cultures (HORCs), which was inhibited by BBG (1 muM).	BzATP	30-35	latexin	Homo sapiens	41-44
23449724-7	2013	RESULTS: P2X7R stimulation by BzATP (100 muM) induced loss of RGC markers in human organotypic retinal cultures (HORCs), which was inhibited by BBG (1 muM).	BzATP	30-35	latexin	Homo sapiens	151-154
23050672-5	2013	In cultures, 2"(3")-O-(4-Benzoylbenzoyl)adenosine-5"-triphosphate (BzATP) activation of P2X7 receptors increased [Ca(2+)]i and induced apoptosis.	BzATP	67-72	purinergic receptor P2X 7	Homo sapiens	88-92
23050672-6	2013	The functionality of the P2X7 receptor was investigated in situ by intrabursal injection of BzATP on each day of the oestrous cycle and evaluation of apoptosis 24h using the terminal deoxyribonucleotidyl transferase-mediated dUTP-fluorescein nick end-labelling (TUNEL) assay.	BzATP	92-97	purinergic receptor P2X 7	Homo sapiens	25-38
23050672-7	2013	Maximum effects of BzATP were observed during pro-oestrus, with the effects being blocked by A438079, a specific P2X7 receptor antagonist.	BzATP	19-24	purinergic receptor P2X 7	Homo sapiens	113-126
21631954-8	2011	In the CA3 region, BzATP infusion attenuated SE-induced neuronal damage, accompanied by enhancement of p65-Ser276 and p65-Ser311 NF-kappaB subunit phosphorylations.	BzATP	19-24	carbonic anhydrase 3	Rattus norvegicus	7-10
21631954-8	2011	In the CA3 region, BzATP infusion attenuated SE-induced neuronal damage, accompanied by enhancement of p65-Ser276 and p65-Ser311 NF-kappaB subunit phosphorylations.	BzATP	19-24	synaptotagmin 1	Rattus norvegicus	103-106
21631954-8	2011	In the CA3 region, BzATP infusion attenuated SE-induced neuronal damage, accompanied by enhancement of p65-Ser276 and p65-Ser311 NF-kappaB subunit phosphorylations.	BzATP	19-24	synaptotagmin 1	Rattus norvegicus	118-121
21631954-10	2011	Soluble TNF p55 receptor (sTNFp55R), and cotreatment with BzATP and sTNFp55R infusion also increased SE-induced neuronal damage in CA3 region.	BzATP	58-63	carbonic anhydrase 3	Rattus norvegicus	131-134
21266468-6	2011	BzATP-mediated secretion involved P2Y(2) receptor signaling because it was reduced by the addition of the ATP scavengers apyrase and adenosine deaminase and the P2Y(2) receptor antagonist suramin.	BzATP	0-5	adenosine deaminase	Mus musculus	133-152
21266468-7	2011	However, the stimulation with BzATP might also release other substances that potentially increase surfactant secretion as a greater stimulation of secretion was observed in AEC II incubated with BzATP when co-cultured with E10 or HEK-293-P2X(7)R cells than with ATP alone.	BzATP	30-35	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	238-245
21266468-7	2011	However, the stimulation with BzATP might also release other substances that potentially increase surfactant secretion as a greater stimulation of secretion was observed in AEC II incubated with BzATP when co-cultured with E10 or HEK-293-P2X(7)R cells than with ATP alone.	BzATP	195-200	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	238-245
19265173-6	2009	Both alpha,beta-meATP and BzATP caused Ca(2+)-dependent binding of phosphorylated p65 (S536) NF-kappaB subunit to the endogenous IL-8 gene promoter in NT-1 cells.	BzATP	26-31	RELA proto-oncogene, NF-kB subunit	Homo sapiens	82-85
19265173-8	2009	Application of alpha,beta-meATP or BzATP at the apical side of polarized human primary nasal epithelial cells sufficed to cause CaMK-dependent IL-8 release by these cells.	BzATP	35-40	C-X-C motif chemokine ligand 8	Homo sapiens	143-147
19265173-6	2009	Both alpha,beta-meATP and BzATP caused Ca(2+)-dependent binding of phosphorylated p65 (S536) NF-kappaB subunit to the endogenous IL-8 gene promoter in NT-1 cells.	BzATP	26-31	C-X-C motif chemokine ligand 8	Homo sapiens	129-133